Modulation of ET-1 responses by ELDP also has implications for treatment of non-cardiovascular diseases, such as cancer and fibrosis, where ETA-receptor antagonists are generally ineffective despite strong evidence that EDN1 expression is involved in disease progression14. The gene discussed is EDN1; the disease is cancer.